MPH Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Medicure (CVE: MPH)
›
Medicure (CVE: MPH) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 3.700 CAD on 19 November 2026, up 266.3% over 52 weeks. Its 52-week range is 0.8500 CAD to 4.950 CAD: the price is 25.3% below the high and 335.3% above the low.
Its market capitalisation is 38.61M CAD.
Medicure reports return on equity of -55.0%, an operating margin of -22.6% and revenue up 11.4% year over year.
It holds more cash than debt, a net cash position of 1.14M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 19 November 2026.